New Study Identifies Specific Obesity-Related Risk Factors for Kidney Cancer
January 16, 2019
GRAND RAPIDS, Mich. – A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma (RCC), a type of kidney cancer, and identifies several specific obesity-related factors.
These factors include multiple measures of obesity, diastolic blood pressure and fasting insulin. In contrast, the study found little evidence for an association with RCC risk for systolic blood pressure, circulating lipids, diabetes or fasting glucose.
“This study provided robust and confirmatory evidence of the important role of obesity and diastolic blood pressure as important risk factors of RCC and novel evidence of an important role of circulating insulin in the disease’s etiology,” said Spectrum Health urologist Richard Kahnoski, MD. “But further research is needed to fully understand these important relationships.”
Renal cell carcinoma is also known as hypernephroma, renal cell cancer and renal cell adenocarcinoma. According to the National Cancer Institute, in 2018 it was estimated that there were 65,340 new cases of kidney and renal pelvis cancer in the U.S. and an estimated 14,970 people died of the disease. Kidney and renal pelvis cancer are the 8th most common cancer type in the U.S., representing 3.8% of all new cancer cases.
The development of RCC has not been fully understood by researchers. An increased risk for the disease has been observed for individuals with high body mass index (BMI), and elevated blood pressure and triglycerides. However, traditional observational studies are subject to confounding and reverse causation errors. This study used an alternative methodology commonly referred to as mendelian randomization, which allows researchers to test for a causal effect from observational data in the presence of confounding factors.
“These obesity-related factors are inherently interrelated, and traditional observational studies have not been able to determine which individual factors directly influence RCC risk and which are merely correlated with the underlying causal factor,” said Brian Lane, MD, PhD, a board-certified urologist and Betz Family Endowed Chair for Cancer Research at Spectrum Health.
“Mendelian randomization allows us to circumvent many of the limitations of traditional observational study by use of genetic proxies of suspected risk factors.”
Lane, along with Kahnoski and colleague Sabrina Noyes, provided investigative and methodological input into the study, which evaluated genetic markers from multiple centers in a genome-wide association study of 10,784 RCC patients and 20,406 control participants. The markers included obesity measures, blood pressure, lipids, type 2 diabetes, insulin and glucose, which were initially identified as instrumental variables.
The study, The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study, was published January 3, 2019 in PLOS Medicine. It was led by Mattias Johansson, PhD, Robert Carreras-Torres, PhD, and Paul Brennan, PhD, of the International Agency for Research on Cancer (IARC), Lyon, France.
Spectrum Health, a not-for-profit, integrated health system, is committed to improving the health and wellness of our communities. We live our mission every day with 31,000 compassionate professionals, 4,200 medical staff experts, 3,200 committed volunteers and a health plan serving 1 million members. Our talented physicians and caregivers are privileged to offer a full continuum of care and wellness services to our communities through 14 hospitals, including Helen DeVos Children’s Hospital, 230 ambulatory sites and telehealth offerings. We pursue health care solutions for today and tomorrow that diversify our offerings. Locally-governed and based in Grand Rapids, Michigan, our health system provided $483 million in community benefit in fiscal year 2018. Thanks to the generosity of our communities, we received $30 million in philanthropy in the most recent fiscal year to support research, academics, innovation and clinical care. Spectrum Health has been recognized as one of the nation’s 15 Top Health Systems by Truven Health Analytics®, part of IBM Watson HealthTM.